Patents by Inventor Nam-Doo Kim

Nam-Doo Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200409253
    Abstract: The present application relates to a method for producing a substrate which includes a step of exposing and developing a photosensitive resin composition layer formed on a surface of a substrate base layer to produce spacers. The method for producing a substrate of the present application can uniformly form spacers having a height according to a desired cell gap and can also freely control the height of the spacers.
    Type: Application
    Filed: November 23, 2018
    Publication date: December 31, 2020
    Applicant: LG Chem, Ltd.
    Inventors: Jun Haeng Lee, Yeon Keun Lee, Jung Doo Kim, Han Min Seo, Cheol Ock Song, Nam Seok Bae
  • Publication number: 20200239474
    Abstract: The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 30, 2020
    Applicants: DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION, NATIONAL CANCER CENTER, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Hwan Geun CHOI, Jong Bae PARK, Eunhwa KO, Jung Beom SON, Joong-heui CHO, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Nam Doo KIM, Yunho LEE, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Jae Hyun BAE, Eunmi HONG, Tae-ho JANG, Sang Bum KIM, Seung Hoon LEE, Do-Hyun NAM
  • Publication number: 20200221921
    Abstract: The present disclosure relates to a dishwasher. The dishwasher, which is installed in a built-in manner in a system kitchen including a cabinet having a receiving space and a counter disposed on the cabinet to include an opening, includes a tub including a front opening, a front door configured to open and close the front opening, a cover frame disposed in the opening of the counter, an upper door rotatably coupled to the cover frame to open and close the opening of the counter, a trigger configured to lock or unlock the upper door, and a lift apparatus disposed to be spaced apart from the trigger and configured to open the upper door by a predetermined angle when the trigger releases the locking of the upper door.
    Type: Application
    Filed: March 28, 2018
    Publication date: July 16, 2020
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyung Kwen HAM, Hyeon Kyu LIM, Yong Soo KYONG, Nam Soo PARK, Chang Wook LEE, Jin Doo KIM
  • Publication number: 20200207756
    Abstract: The present invention relates to a pyrrolopyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 2, 2020
    Inventors: Hwan Geun CHOI, Eunhwa KO, Joong-heui CHO, Jung Beom SON, Yi Kyung KO, Jin-Hee PARK, So Young KIM, Seock Yong KANG, Seungyeon LEE, Hee Yoon RYU, Nam Doo KIM, Sang Bum KIM, Sun-Hwa LEE, Dayea KIM, Sun Joo LEE, Sungchan CHO, Kyu-Sun LEE, Kweon YU, Miri CHOI, Ja Wook KOO, Hyang-Sook HOE
  • Patent number: 10473562
    Abstract: A corrugated constant pressure cylinder apparatus having no micro leaks and its method of use. The internal pressure of the corrugated cylinder (b10) is maintained at a constant pressure so as to allow for transport or storage in a state without micro leaks. The corrugated constant pressure cylinder apparatus is able to keep substances that exist in gaseous or liquid form at room temperature such as mixed refrigerant gases, volatile organic compounds (VOC), hydrocarbon mixtures-in liquid form, or is able to keep the pressure constant even if the internal volume changes due to the contents inside the cylinder.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 12, 2019
    Assignee: Korea Research Institute of Standards and Science
    Inventors: Jin Choon Woo, Yong Doo Kim, Hyeon Gil Bae, Nam Goo Gang
  • Patent number: 10442796
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 15, 2019
    Assignees: Korea Institute of Science and Technology, Daegu-Gyeongbuk Medical Innovation Foundation
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Publication number: 20190047993
    Abstract: The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 14, 2019
    Inventors: Tae Bo Sim, Woo Young Hur, Chi Man Song, Ho Jong Yoon, Seung Hye Choi, Han Na Cho, Hwan Geun Choi, Nam Doo Kim, Jung Beom Son, Eun Hwa Ko, Hyun Kyoung Kim, Joong Heui Cho, Seock Yong Kang, So Young Kim, Yi Kyung Ko, Seung Yeon Lee, Suk Kyoon Yoon, Jae Hyun Bae
  • Patent number: 9216981
    Abstract: A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like.
    Type: Grant
    Filed: November 25, 2011
    Date of Patent: December 22, 2015
    Assignee: Medpacto, Inc.
    Inventors: Eun Kyong Shim, Nam Doo Kim, Tae Bo Shim, Seung Yong Kim
  • Publication number: 20130317023
    Abstract: A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like.
    Type: Application
    Filed: November 25, 2011
    Publication date: November 28, 2013
    Applicant: YOUAI CO., LTD.
    Inventors: Eun Kyong Shim, Nam Doo Kim, Tae Bo Shim, Seung Yong Kim
  • Patent number: 7816351
    Abstract: Disclosed herein are 5,?-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,?-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: October 19, 2010
    Assignee: Equispharm Co., Ltd
    Inventors: Cheol Kyu Han, Jeonghyeok Yoon, Nam-Doo Kim, Jin-ah Kim
  • Publication number: 20080234482
    Abstract: Disclosed herein are 5,?-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,?-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.
    Type: Application
    Filed: September 23, 2005
    Publication date: September 25, 2008
    Applicant: EQUISPHARM CO., LTD
    Inventors: Cheol Kyu Han, Jeonghyeok Yoon, Nam-Doo Kim, Jin-ah Kim
  • Publication number: 20070149613
    Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angiogenesis, and also a method for preparing the same.
    Type: Application
    Filed: November 21, 2006
    Publication date: June 28, 2007
    Inventors: Cheol-Kyu Han, Jeong-Hyeok Yoon, Seung-Moak Kim, Nam-Doo Kim, Byung-Ha Chang, Jee-Young Lee, Tae-Bo Sim
  • Publication number: 20060276512
    Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angiogenesis, and also a method for preparing the same.
    Type: Application
    Filed: July 26, 2006
    Publication date: December 7, 2006
    Inventors: Cheol-Kyu Han, Jeong-Hyeok Yoon, Seung-Moak Kim, Nam-Doo Kim, Byung-Ha Chang, Jee-Young Lee, Tae-Bo Sim
  • Patent number: 7087768
    Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angeogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angeogeneois, and also a method for preparing the same.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: August 8, 2006
    Assignee: Equispharm Co., Ltd.
    Inventors: Cheol-Kyu Han, Jeong-Hyeok Yoon, Seung-Moak Kim, Nam-Doo Kim, Byung-Ha Chang, Jee-Young Lee, Tae-Bo Sim
  • Publication number: 20040242681
    Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angeogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angeogeneois, and also a method for preparing the same.
    Type: Application
    Filed: March 23, 2004
    Publication date: December 2, 2004
    Inventors: Cheol-Kyu Han, Jeong-Hyeok Yoon, Seung-Moak Kim, Nam-Doo Kim, Byung-Ha Chang, Jee-Young Lee, Tae-Bo Sim
  • Patent number: 6762189
    Abstract: The present invention relates to novel 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives, and more specifically, to 5-pyrimidinecarboxamide derivatives and their pharmacutically able salts, the process for preparing them, and the pharmaceutical compositions containing said compounds as active ingredients. In particular, said 5-pyrimidinecarboxamide derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as a therapeutic agent as well as a preventive agent for hepatitis B and acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: July 13, 2004
    Assignee: Dong Wha Pharm. Ind. Co., Ltd.
    Inventors: Sung June Yoon, Sang Wook Lee, Nam Doo Kim, Yong Kyun Park, Geun Hyung Lee, Jong Woo Kim, Sang Jin Park, Hee Jeoung Park, Hwan Bong Jang
  • Patent number: 6753430
    Abstract: The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active quinoline carboxylic acid derivatives containing 4-aminomethyl-4methyl-3-(Z)-alkoxyiminopyrrolidine substituents causing optical activity at the 7-position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: June 22, 2004
    Assignee: Dong Wha Pharm. Ind. Co., Ltd
    Inventors: Sung June Yoon, Yong Ho Chung, Chi Woo Lee, Jin Soo Lee, Nam Doo Kim, Yoon Ho Jin, Wan Jin Song, Ik Hoe Kim, Wang Yong Yang, Dong Rack Choi, Jung Han Shin
  • Patent number: 6743795
    Abstract: The present invention relates to novel 3-nitropyridine derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same as active ingredients. Methods of preparing the derivatives and pharmaceutical compositions containing the same are also disclosed. The 3-nitropyridine derivatives of the present invention, due to their inhibitory activity against the proliferation of human immunodeficiency virus (HIV) as well as hepatitis B virus (HBV), can be used as therapeutic agents as well as preventive agents for hepatitis B and acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: June 1, 2004
    Assignee: Dong Wha Pharm. Ind. Co. Ltd.
    Inventors: Sung June Yoon, Sang Wook Lee, Nam Doo Kim, Yong Kyun Park, Geun Hyung Lee, Jong Woo Kim, Sang Jin Park, Hee Jeoung Park, Dong Hyuk Shin
  • Publication number: 20040029915
    Abstract: The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active)quinoline carboxylic acid derivatives containing 4-aminomethyl-4-methyl-3-(Z)-alkoxyiminopyrrolidine substituents causing optical activity at the 7-position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.
    Type: Application
    Filed: June 20, 2003
    Publication date: February 12, 2004
    Inventors: Sung June Yoon, Yong Ho Chung, Chi Woo Lee, Jin Soo Lee, Nam Doo Kim, Yoon Ho Jin, Wan Jin Song, Ik Hoe Kim, Wang Yong Yang, Dong Rack Choi, Jung Han Shin
  • Patent number: 6649763
    Abstract: The present invention relates to optically active quinoline carboxylic acid derivatives, their pharmaceutically acceptable salts, their solvates, and a process for the preparation thereof. More specifically, the present invention relates to optically active quinoline carboxylic acid derivatives containing 4-aminomethyl-4-methyl-3-(Z)-alkoxyirninopyrrolidine substituents causing optical activity at the 7-position of the quinolone nuclei. As the compounds of the present invention have superior antibacterial activity and pharmacokinetic profiles to their enantiomers, their racemates and conventional antibacterial agents, with nearly no phototoxicity, the compounds of this invention are useful for antibacterial agents.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: November 18, 2003
    Assignee: Dong Wha Pharm. Ind. Co., Ltd.
    Inventors: Sung June Yoon, Yong Ho Chung, Chi Woo Lee, Jin Soo Lee, Nam Doo Kim, Yoon Ho Jin, Wan Jin Song, Ik Hoe Kim, Wang Yong Yang, Dong Rack Choi, Jung Han Shin